Podcasts about flow cytometry

It could be argued that biology has always boiled down to chemistry, and that chemistry has always boiled down to physics. However, not many would deny that the fields of biology and chemistry are overlapping more than ever, with both leveraging computing methods, also more than ever. This conversation with Dr. Ramesh Jha, Technical Staff Member at Los Alamos National Laboratory (LANL), crosses biology, chemistry, and computing methods. The work of his biome team at LANL uses computational tools to inform the design of enzymes that are produced via PCR-based cloning and then expressed in microbes. They use fluorescent gene circuits in these microbes, along with flow cytometry, to screen these large libraries for advantageous gain-of-function variants. When they find an interesting mutation, they isolate it, sequence it, and produce and evaluate those biocatalytic enzymes for bioremediation, biomanufacturing, and other important applications. Ramesh makes this complex and interdisciplinary science approachable and gives hope to how it could help address problems of “forever chemicals” and other environmental and manufacturing challenges. Join us for this interesting and inspiring conversation.  Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Send us a Text Message.Curious about the latest innovations in cell analysis technology? Join us in this episode with Furkan Gökçe, New Business Development Manager at Amphasys, as we delve into the fascinating world of Impedance Flow Cytometry (IFC).Furkan shares how IFC is revolutionizing single-cell analysis by providing faster, more precise, and high-resolution data.Key Takeaways:Real-Time Precision: Discover how IFC allows for real-time, label-free assessments of cells, providing detailed insights into their natural state.Enhanced Process Control: Learn how IFC can detect early signs of nutrient deficiencies and contaminants, leading to timely interventions and improved bioreactor outcomes.Versatile Applications: Hear about practical applications, from brewing to protein production, where IFC has significantly boosted yields and process efficiency.Tune in to uncover how IFC is set to transform the landscape of bioprocessing, ensuring better quality and sustainability in biologics production.Connect with Furkan Gökçe:LinkedIn: https://www.linkedin.com/in/furkangokceAmphasys: https://amphasys.com/bioprocessingNext Steps:Book a free assessment to help you get started with the implementation of new technologies in your manufacturing processes: https://bruehlmann-consulting.comDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a Text Message.Ever wondered how single-cell analysis could revolutionize bioprocessing? Join us in this episode as we delve into the cutting-edge world of impedance flow cytometry.Furkan Gökçe, New Business Development Manager at Amphasys, shares his insights on the transformative power of this technology in the biotech industry. With a background in engineering and physics, Furkan provides a unique perspective on tackling the complexities of biological systems.Key Takeaways:Enhanced Process Control: Learn how impedance flow cytometry offers high-resolution, label-free analysis of individual cells, ensuring optimal growth conditions and quality production.Understanding Cell Heterogeneity: Discover the importance of single-cell analysis in revealing critical variations within cell populations that bulk measurements often miss.Innovation in Bioprocessing: Explore the advancements in microfabrication techniques that make real-time, high-throughput cell analysis possible, revolutionizing bioprocessing efficiency and accuracy.Tune in to gain valuable knowledge on how this innovative technology can enhance your bioprocess development and manufacturing strategies!Connect with Furkan Gökçe:LinkedIn: https://www.linkedin.com/in/furkangokceAmphasys: https://amphasys.com/bioprocessingNext Steps:Book a free assessment to help you get started with the implementation of new technologies in your manufacturing processes: https://bruehlmann-consulting.comDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Flow cytometry technologies and cancer associated fibroblasts and Leveraging flow cytometry in drug discovery. In the first article, Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done. In the second article, Dr Miguel A Tam, and Dr Kenta Yamamoto, BioLegend, examine the evolution, trends and best practices for smooth and efficient workflows for flow cytometry. You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Nirvana Sciences has innovated traditional flow cytometry, a longstanding cellular diagnostic tool, in a unique and powerful way to dramatically increase the efficiency and utility of this tool for a wide range of diagnostic problems. Through development of proprietary bright narrowband fluorescent markers (or dyes), NS has enabled a magnitude increase in the number, fidelity and efficiency of cell markers that can be measured from a single sample. This has positioned NS with strong IP for an acquisition by a major diagnostics company.We invite your feedback and suggestions at ventureinthesouth.com or email david@ventureinthesouth.com. If you like the podcast, leave us a review and share with your friends! Follow David and Paul on LinkedIn to stay updated on the newest episodes. To learn more about the RollingSouth Funds, visit rollingsouth.vc or email david@rollingsouth.vc. Thanks for listening and remember: Our mission is to MAKE MONEY, HAVE FUN AND DO GOOD

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.24.550259v1?rss=1 Authors: Howell, J., Omwenga, S., Jimenez, M., Hammarton, T. C. Abstract: Promastigote Leishmania mexicana have a complex cell division cycle characterised by the ordered replication of several single-copy organelles, a prolonged S phase and very rapid G2 and cytokinesis phases, accompanied by cell cycle stage-associated morphological changes. Here we exploit these morphological changes to develop a high-throughput and semi-automated imaging flow cytometry (IFC) pipeline to analyse the cell cycle of L. mexicana in live cells. Firstly, we demonstrate that, unlike several other DNA stains, Vybrant DyeCycle Orange (DCO) is non-toxic and enables quantitative DNA imaging in live L. mexicana promastigotes. Secondly, by tagging the orphan spindle kinesin, KINF, with mNeonGreen, we describe KINFs cell cycle-dependent expression and localisation. Then, by combining manual gating of DCO DNA intensity profiles with automated masking and morphological measurements of parasite images, visual determination of the number of flagella per cell, and automated masking and analysis of mNG:KINF fluorescence, we provide a newly detailed description of L. mexicana promastigote cell cycle events that, for the first time, includes the durations of individual G2, mitosis and post-mitosis phases. By applying IFC in this way, we were able, in minutes, to capture tens of thousands of high quality brightfield and fluorescent images of live L. mexicana cells in solution, and to acquire quantitative data across multiple parameters for every image captured. Our custom-developed masking and gating scheme, allowed us to identify elusive G2 cells, show that cytokinesis commences during early mitosis and continues after mitosis is complete, and identify newly divided cells that were within the first 12 minutes of the new cell cycle. Our new pipeline offers many advantages over traditional methods of cell cycle analysis such as fluorescence microscopy and flow cytometry and paves the way for novel high-throughput analysis of Leishmania cell division. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.14.549082v1?rss=1 Authors: Brahmer, A., Geiss, C., Lygeraki, A., Neuberger, E., Tzaridis, T., Nguyen, T. T., Luessi, F., Regnier-Vigouroux, A., Hartmann, G., Simon, P., Endres, K., Bittner, S., Reiners, K. S., Kramer-Albers, E.-M. Abstract: Extracellular vesicles (EVs) derived from the CNS are potential liquid-biopsy markers for early detection and monitoring of neurodegenerative diseases and brain tumors. This study assessed the performance of a bead-based flow cytometry assay (EV Neuro) for multiparametric detection of CNS-derived EVs and identification of disease-specific markers. Different sample materials and EV isolation methods were compared. Glioblastoma- and primary human astrocyte-derived EVs exhibited distinct EV profiles, with signal intensities increasing with higher EV input. Analysis of serum or plasma from glioblastoma, multiple sclerosis, Alzheimers Disease patients and healthy controls showed varying marker signal intensities. Notably, data normalization improved marker identification. Specific EV populations, such as CD36+EVs in glioblastoma and GALC+EVs in multiple sclerosis, were significantly elevated in disease compared to controls. Clustering analysis techniques effectively differentiated glioblastoma patients from controls. A potential correlation between CD107a+EVs and neurofilament levels in the blood was identified in multiple sclerosis patients. Together, the semi-quantitative EV Neuro assay demonstrated its utility for EV profiling in complex samples. However, reliable statistical results in biomarker studies require large sample cohorts and high effect sizes. Nonetheless, this exploratory trial confirmed the feasibility of discovering EV-associated biomarkers and monitoring circulating EV profiles in CNS diseases using the EV Neuro assay. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.06.547972v1?rss=1 Authors: Sharp, R. C., Farrer, M. J. Abstract: Objective: To systematically review the neuroimmunology literature to determine the average immune cell counts reported by flow cytometry in wild-type (WT) homogenized mouse brain. Background: Mouse models of gene dysfunction are widely used to study age-associated neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. The importance of the neuroimmune system in multifactorial disorders has become increasingly evident, and methods to quantify resident and infiltrating immune cells in brain, including flow cytometry, have been applied numerous times. However, there appears to be no consensus on the best approach to perform flow cytometry, to quantify immune cell counts or report them. The development of more standardized methods would accelerate neuroimmune discovery and validation through meta-analyses. Methods: Examination of the PROSPERO registry confirmed a systematic review of 'neuroimmunology' by 'flow cytometry' has yet to be reported. A protocol for a systematic review was subsequently based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) using Studies, Data, Methods and Outcomes (SDMO) criteria. Literature searches were conducted in Google Scholar and PubMed databases. From that search, 870 candidate studies were identified and 417 studies were assessed for eligibility based on formal exclusion criteria. Results: Out of the 417 studies reviewed, 52 were eligible for inclusion and comparative analysis. Each study assessed immune cell subsets within homogenized mouse brain and used flow cytometry. Nonetheless, there was considerable variability in methods, data analysis, reporting and results. Descriptive statistics are presented on study designs and results, including medians with interquartile ranges (IQRs) and overall means with standard deviations (SD) for specific immune cell counts and their relative proportions, within and between studies. Conclusion: Experiments to conduct and report flow cytometry data, derived from homogenized mouse brains, would benefit from a more standardized approach. While within study comparisons are valid, variability in methods, counts and proportions of immune cell populations are too broad for meta-analysis. However, inclusion of a minimal protocol with more detailed methods, controls and standards could enable this nascent field to compare results across studies. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

This discussion with Dr. Johan Skog covers a lot of ground while staying super approachable. The Founder and Chief Scientific Officer of Exosome Diagnostics, starts by sharing basics about exosomes and tells us about how he's translated his curiosity for the vesicles from tumor stem cells into his current role where he's helped develop the world's first exosome-based cancer diagnostic test. The conversation delves into the variations in exosomes populations, the value of using multiple biomarkers in diagnostics, the role that isolation and purification play in using exosomes for diagnostics, and why some cancers are better left untreated. Join us for this fascinating conversation with an innovator, that just happens to have one of the most soothing voices around. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit https://thermofisher.com/molbioschool to access the Invitrogen School of Molecular Biology, which is packed with really helpful molecular biology resources and educational content. Experience the Speaking of Mol Bio podcast in its extended video format for a more immersive journey, while also ensuring accessibility with downloadable transcripts for each episode. Watch now at thermofisher.com/podcast-video

Just released, the new Color Atlas of Flow Cytometry offers a full range of hematolymphoid disease cases, highlighting disease categories and disease entities that may be difficult to diagnose in clinical practice. The new book can benefit students, medical technologists, and practicing pathologists, explains lead author, David Dorfman, MD, PhD, FCAP in this CAPcast interview. To purchase this book, please visit CAP's estore: https://estore.cap.org/OA_HTML/xxCAPibeCCtpItmDspRte.jsp?section=10044&item=747354&sitex=10020:22372:US

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.03.21.533670v1?rss=1 Authors: Faber, G. P., Hauschner, H., Atrash, M. K., Bilinsky, L., Shav-Tal, Y. Abstract: Endogenous gene knock-in using CRIPSR is becoming the standard for fluorescent tagging of endogenous proteins. Some protocols, particularly those that utilize insert cassettes that carry a fluorescent protein tag, can yield many types of cells with off-target insertions that have diffuse fluorescent signal throughout the whole cell in addition to scarce cells with on-target gene insertions that show the correct sub-cellular localization of the tagged protein. As such, when searching for cells with on-target integration using flow cytometry, the off-target fluorescent cells yield a high percentage of false positives. Here, we show that by changing the gating used to select for fluorescence during flow cytometry sorting, namely utilizing the width of the signal as opposed to the area, we can highly enrich for positively integrated cells. Reproducible gates were created to select for even minuscule percentages of correct subcellular signal, and these parameters were validated by fluorescence microscopy. This method is a powerful tool to rapidly enhance the generation of cell-lines with correctly integrated gene knock-ins encoding endogenous fluorescent proteins. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In this episode, Megan McCausland, Scientific Advisor for Flow Cytometry at Q2 Solutions, and Scott Bornheimer, Associate Director of Medical and Scientific Affairs at BD Biosciences talk about the enormous potential of flow cytometry as a clinical diagnostic tool.  Currently, pharma companies are looking for simplified, standardized flow cytometry tests to help with enrolling patients and understanding outcomes in their studies.  In the longer term, Megan McCausland notes what will lead to the use of flow as a CDx: “I think the drug development landscape really continues to evolve towards more personalized medicine. As this happens, biomarkers and their potential translation into companion diagnostics are playing an ever-increasingly important role. The regulatory bodies are pushing, perhaps even expecting, this co-development of biomarkers and treatments with CDx really becoming vital to regulatory approval and clinical use.” - Megan McCausland To learn more visit q2labsolutions.com/flow-cytometry

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.11.516066v1?rss=1 Authors: Thomas, R. A., Sirois, J. M., Li, S., Gestin, A., Piscopo, V. E., Lepine, P., Mathur, M., Chen, C. X. Q., Soubannier, V., Goldsmith, T. M., Fawaz, L., Durcan, T. M., Fon, E. A. Abstract: With the recent surge of single cell RNA sequencing datasets (scRNAseq) the extent of cellular heterogeneity has become apparent, yet it remains poorly characterized on a protein level in brain tissue and induced pluripotent stem cell (iPSC) derived brain models. With this in mind, we developed a high-throughput, standardized approach for the reproducible characterization of cell types in complex neuronal tissues. We designed a flow cytometry (FC) antibody panel coupled with a computational pipeline to quantify cellular subtypes in human iPSC derived midbrain organoids. Our pipeline, termed CelltypeR, contains scripts to transform and align multiple datasets, optimize unsupervised clustering, annotate cell types, quantify cell types, and compare cells across conditions. We identified the expected brain cell types, then sorted neurons, astrocytes, and radial glia, confirming these cell types with scRNAseq. We present an adaptable analysis framework providing a generalizable method to reproducibly identify cell types across FC datasets. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.10.515864v1?rss=1 Authors: von Lersner, A. K., Fernandes, F. C. L., Ozawa, P. M. M., Vagner, T., Lima, S. M., Sung, B. H., Wehbe, M., Franze, K., Wilson, J. T., Irish, J. M., Weaver, A., Di Vizio, D., Zijlstra, A. Abstract: Mammalian cells release a heterogeneous array of extracellular vesicles (EVs) that impact human biology by contributing to intercellular communication. To resolve EV heterogeneity and define the EV populations associated with specific biological processes, we developed a method named "EV Fingerprinting" that discerns distinct vesicle populations using dimensional reduction of multi-parametric data collected by quantitative single-EV flow cytometry. After validating this method against synthetic standards, the EV Fingerprinting analysis of highly purified EVs enabled a much more granular resolution of biochemically distinct EV populations than previously established methods. The analysis of EVs produced after molecular perturbation of EV biogenesis through ablation of the GTPase Rab27a and overexpression of the tetraspanin CD63 revealed that EV Fingerprinting reflects the molecular state of a cell. Subsequent analysis of human plasma demonstrates the capacity of EV Fingerprinting to resolve EV populations in complex biological samples and detect tumor-cell derived EVs. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Flow cytometry with Dr. Vermeer - Ruxolitinib cream for vitiligo - Baricitinib for AA - Roflumilast for psoriasis - Tapinarof for psoriasis - Connect with Dr. Vermeer! https://www.universiteitleiden.nl/en/staffmembers/maarten-vermeer#tab-1 Connect with us! Web: https://dermaspherepodcast.com/ Twitter: @DermaspherePC Instagram: dermaspherepodcast Facebook: https://www.facebook.com/DermaspherePodcast/ Check out Luke and Michelle's other podcast, SkinCast! https://healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: Kikoxp.com (a social platform for doctors to share knowledge) https://www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!)

#2 — Season 3. Grace Chojnowski is Flow Cytometry and Imaging Facility Manager at the Queensland Institute of Medical Research. In this episode of Flow Stars, Grace joins Peter O'Toole to discuss why understanding the theory behind your experiment is key in flow cytometry, why she'd like a flow lab in the Alps, and her early career as an Australian living in London. We also hear about a funny interview story and talk candidly about how she avoided the stress of isolation and burnout at the start of her career. Watch or listen to all episodes of Flow Stars here: https://bitesizebio.com/flowstars/ #FlowStars #FlowCytometry #Podcast #BitesizeBio

#S3:E2 — Grace Chojnowski is Flow Cytometry and Imaging Facility Manager at the Queensland Institute of Medical Research.In this episode of Flow Stars, Grace joins Peter O'Toole to discuss why understanding the theory behind your experiment is key in flow cytometry, why she'd like a flow lab in the Alps, and her early career as an Australian living in London. We also hear about a funny interview story and talk candidly about how she avoided the stress of isolation and burnout at the start of her career.Watch or Listen to all episodes of Flow Stars here: https://flowstars.bitesizebio.com

Flow cytometry for CGT assay development: an interview with Richard Cuthbert by Future Science Group

Dr Barry Moran core facility manager of the Flow Cytometry Facility, at the Trinity Biomedical Sciences Institute is my guest this week. He chats to me about his 'unconventional' journey through academia, deciding to do a part time PhD while running the Cytometry core facility and why the 'journey-man' in him may be relatable.  Barry also discusses how flow cytometry can advance our scientific knowledge and its benefits particularly in the context of immunology. He describes his own research examining immune dysfunction in the skin disease hidradenitis suppurativa and why this is research that adds value to patients lives. Follow Barry: tcdflow Follow me: MeganHanlon4 This season is kindly sponsored by Bio-Sciences Ltd, now part of Thermo-Fisher Scientific.

Major Points Covered: In Part 1 of our Heme Path series, we break down the logistics and applications of flow cytometry.Take aways: 1. Cancer = cells that clone themselves uncontrollably due to mutations.2. Purpose of flow cytometry is to assess phenotype of the cell by characterizing cell surface markers (CD markers for example). For blood cells, this is called the “immunophenotype”.3. Testing requires live cells in suspension and can't be fixed. Remember to keep all lymph node biopsies in suspension when sending for flow cytometry. 4. Flow tells us that if cells share the same abnormal expression of cell surface markers, they are clonal and therefore raise concern for cancer. 5. Flow tells us if cells have specific cell surface markers that we can target for treatment. For example, expression of CD20 can be targeted by the drug Rituximab. 6. If a clone is identified at diagnosis, flow cytometry can be used to sift through thousands of cells to see if a single clone with the original abnormal phenotype is left over. This is called minimal residual disease (MRD) testing and is a great way to monitor response to treatment and identify if any tiny amount of cancer is left over. 7. There are a variety of indications to send flow cytometry but the bottom line to remember is that we are trying to find an abnormal clonal population of cells. You may not see anything abnormal in the peripheral blood because those cells are living in the bone marrow. 8. Blasts reported on the CBC w/ diff is done based on visual inspection of morphology by a hematology lab scientist or pathologist; but can only confirm if it is truly a blast with flow cytometry. 9. Always send bone marrow biopsy aspirate samples for flow cytometry. 10. We use flow cytometry as one piece of the larger puzzle to prove clonality and make a diagnosis. Other uses are for determination of targeted treatments based on cell surface markers and to identify any amount of residual disease (MRD testing by flow cytometry).References:https://ashpublications.org/blood/article/111/8/3941/24550/Flow-cytometric-immunophenotyping-for-hematologic - ASH review article on use of flow cytometry to diagnose heme malignancies. https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.20365 - Bethesda International Consensus Guidlines for Flow Cytometry in 2006https://www.bloodresearch.or.kr/journal/view.html?uid=2357&vmd=Full& - Minimal residual disease testing in ALL as an example of another clinical use of flow cytometry http://www.cyto.purdue.edu/archive/flowcyt/research/pdfs/encyclopedia_2004.pdf - Good article explaining the complexities of the flow cytometry technique Please visit our website (TheFellowOnCall.com) for more information Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Enrico Lugli, Humanitas Milano, Italy speaks on "High content flow cytometry to dissect memory T cell responses". This video is part of Course “Flow cytometry: from basic principles to advanced applications-CytoFlow@ICGEB”, an online event 28-30 September 2021. For more informations please visit https://www.icgeb.org.

Stefania Arioli, UniMIlano, Italy speaks on "Flow cytometry applications in Food Microbiology: not only cell counting!". This video is part of Course “Flow cytometry: from basic principles to advanced applications-CytoFlow@ICGEB”, an online event 28-30 September 2021. For more informations please visit https://www.icgeb.org.

(00:32):Before we get into the test itself, Dr. Mills, I'd love for you to tell our audience just a little bit about yourself, your background, your role here at Mayo clinic. (01:41):Can you just give our audience a brief overview of the assay? (05:20):I really appreciate how the lab has looked at other approaches and decided that this is the best one. Is that an accurate kind of summary. (06:16):They'll get the result that they need with just one test, right? (07:03):So can you start with helping our physicians understand which patients should get this testing? (09:05):You said these immune mediated neuropathies, this test is going to be important for all of those to help, to identify the distinct phenotype of neurofascin155, right, Dr. Mills? (09:43):I know you mentioned that these are rare disorders, but how common is the neurofascin antibody in that phenotype? (11:27):Dr. Mills, are there any other alternative options regarding this kind of testing? (13:30):How is the positive or negative result going to drive the physician in a certain direction regarding prognosis or treatment? Can you share some of that? (14:48):Do you think there are any prerequisites that physicians should be testing for these particular things before they would order our neurofascin test or does the neurofascin come pretty early on in the differential? (15:36):Can you elaborate a little more on the next steps? What does a more aggressive treatment plan? What does that mean? (16:09):We've talked about a lot of the important items, the assay and how it's designed, how this is going to help patient care and how it's unique, but what's your key takeaway here? What are you most excited about?

The clinical laboratory workforce is crucial to the U.S. healthcare system, providing critical information in the diagnosis, treatment, and management of disease. And yet, the number of laboratory professionals continues to shrink. What can we do to reverse this trend? On this episode of Inside the Lab, Dr. Lotte Mulder and guest host Ms. Edna Garcia, Director of Scientific Engagement and Research at ASCP's Institute for Science, Technology and Policy in Washington, DC, are joined by Ms. Susan Skillman, MS, Senior Deputy Director of the University of Washington Center for Health Workforce Studies, and Ms. Allyson Flores, MLS(ASCP)CM, Manager of Flow Cytometry and Hematopathology at Children's National Hospital in Washington, DC, to discuss workforce policy. Our panelists describe ASCP's ongoing research around wage and vacancy, including the most recent Clinical Laboratory Workforce report produced in conjunction with the University of Washington's Center for Health Workforce Studies. They explain the most critical challenges facing our workforce today, exploring how to increase the visibility of careers in the lab, improve recruitment and retention, and promote diversity and inclusion in the field of laboratory medicine. Listen in for insight on how the pandemic is likely to shape the future of the profession and learn how you can help implement the innovative strategies proposed in the ASCP-UW CHWS report. Topics Covered  · ASCP's ongoing research around wage and vacancy in the clinical laboratory profession· ASCP's partnership with the UW Center for Health Workforce Studies on the most recent Clinical Laboratory Workforce Report · Critical challenges currently facing the clinical laboratory workforce· Why diversity is essential to the future of the profession and what we can do to recruit a more diverse clinical laboratory workforce· What attracted our panelists to laboratory medicine and how we might leverage those aspects of the career to address recruitment· Opportunities for institutions to communicate with local medical laboratory science programs around what trainees need to know· What the report teaches us about professional development opportunities and wage progression that might inform our practices moving forward Connect with ASCP ASCPASCP on FacebookASCP on InstagramASCP on Twitter Connect with Ms. Skillman Ms. Skillman on TwitterMs. Skillman at UW CHWS Connect with Ms. Flores Ms. Flores on TwitterMs. Flores on LinkedIn Connect with Dr. Mulder & Ms. Garcia Dr. Mulder on TwitterMs. Garcia on LinkedIn Resources ASCP's Clinical Laboratory Workforce ReportInside the Lab in the ASCP Store 

Flow Cytometry is a critical tool that researchers use to find vaccines and cures for diseases. In this episode, we will find out how one senior product owner at BD, Howie Seay, leverages digital innovation to expedite this scientific research process in an attempt to curb the spread of the future pandemic.

This episode is also available as a blog post: https://mdforlives.blog/2021/06/21/flow-cytometry-in-cancer-diagnosis-and-immune-system-disorders/ --- Send in a voice message: https://anchor.fm/mdforlives/message

This narrated article is called “Why flow cytometry in drug discovery is a real life-saver”, in which Roy, Global Product Manager at Miltenyi Biotec, outlines the benefits of flow cytometry, offering case study examples for its use. Capable of boasting high-throughput, accurate, multiparameter and highly reproducible results, it’s time for drug discovery industries to look again at how flow cytometry can be successfully utilised within challenging processes.

Immigrant Entrepreneur: Giacomo Vacca Doctor Giacomo Vacca leaves his hometown at the age of 16 because he always wanted to become a scientist. Leaving your country behind at 16 is not only considered bravery, but beyond courageous.  After graduating Harvard, he attended Stanford University to obtain his PhD in Applied Physics. This lead him on a path to getting amazing jobs at different companies including one that was a Fortune 500 company. He quickly realized that he was meant for something bigger. Deep down on the inside he always had an entrepreneurial drive so he quit and ventured off to create Kinetic River Corp.  In this episode he explains how he was able to gain his customers without doing much of any marketing and gives us incredible advice on immigrant entrepreneurship.  Where to find Doctor Giacomo Vacca:  Kinetic River Corp. | LinkedIn Where to find me:  alinawarrick.com hello@alinawarrick.com Get first month FREE with Audible (affiliate links included)  

Water is the lifeline of your dental practice. If your dental unit waterlines are covered in biofilm, you’re in trouble. How do you test your water lines properly? How do you treat your systems? What do you do if you don’t have a closed system? With the heightened awareness of spreading germs due to the Coronavirus crisis, it’s more important than ever to be mindful of prevention in your practice. In this episode of Talking with the Toothcop, Dwight and I chat with Mike Rust and Kellie Thimmes from ProEdge Dental about what dentists can—and should be doing—to prevent infections.  Outline of This Episode [0:21] Mike Rust + Kellie Thimmes on the Toothcop [1:19] What people don’t know about Kellie + Mike [4:27] How to test your water lines properly [11:40] The CDC will revise dental infection control guidelines [20:40] Indicators that a dental office does or doesn’t care [28:28] Where does the problem originate? [31:58] Pro Edge’s new Flow-Cytometry technology [38:15] The Anaheim case that changed everything [42:01] What could happen when the CDC reviews their guidelines? [43:33] What do you do about open systems [55:17] UV disinfection technology [58:25] How to connect with Mike + Kellie Why biofilms originate in water lines Biofilms usually form in waterlines because they’re small, plastic, and the water sits stagnant. The bacteria sits there and thrives. It can also be found in anything with a filtration system—which can remove solids (like minerals and chlorine) but not small bacteria. So everything just sits there in their little pod and it’s the perfect breeding ground for bacteria. That’s why it’s so important to purge anything connected to your waterline unit. The extra flow of water in between patients helps move the germicide through the system and helps keep it clean—and prevents biofilms.  The Texas dental board recently relaxed its Cavitron regulations to allow dentists to start using them again. Most dentists haven’t been using them since mid-march of 2020. Why? Kellie points out that firstly, they create aerosols. Secondly, water lines tend to hold a lot of bacteria. Dentists don’t want to worry about COVID and other bacteria. It’s also because Cavitrons are harder to shock. The failure rate is over 50% and they have higher counts of CFU’s than any other water line. How to properly test your dental unit waterlines  You have to collect the water for the test from the right place. 9/10 times dentists that say they’re testing pull a sample from an air-water syringe. But dentists should be testing from the dirtiest thing(s) in the dental practice: a water sample from the Cavitron or Ultrasonic. If you’re passing your water test with samples from those you know you’re doing well.  Kellie recommends taking a collective sample from each room in your dental practice If there’s a failure, then you shock everything. Both Kellie and Mike advise using an aseptic technique when you’re taking a sample. Take the handpiece off and use a new air water syringe tip. It’s not as messy and easier to collect the sample. Test your water as if you were doing it for a new patient.  Are the current infection control guidelines enough? It was recently announced that the CDC will be revising dental infection control guidelines—which has been overdue for a while. It makes you question: Are the current guidelines as effective as we think they are? The CDC recommends periodic testing but doesn’t define the timeline. They say to defer to the manufacturer's instructions. You have to monitor your water regularly—at least quarterly if not monthly. Kellie and Mike agree that you must use an EPA approved shock product.  If you’re not aware, the EPA regulates drinking water standards and anything that could impact groundwater. The FDA regulates medical devices (they review and approve). Everything you use in the dental office is a medical device. For you to use it, the manufacturer had to get approval from the FDA. Whenever you deviate or use a device other than its intended use, it’s considered off-label use.  There are a lot of treatments for removing biofilm, so you have to find what works for your practice. Follow the IFUs for the products you’ve chosen and ask for help if you need it. Kellie states “I wish there was a magic bullet, but there’s just not. It’s called waterline maintenance for a reason—because it takes work.” If you’re committed to monitoring, you’ll get better results.  What are indicators that a dental office is doing what they’re supposed to for infection prevention? Listen to hear their take! Sometimes you have to humanize the problem The case that happened in Anaheim, CA impacted 71 families. 70 of the kids had major surgeries and some lost parts of their jaw from preventable infections. All because ONE dentist office didn’t properly test or treat their water lines.  Some dentists don’t want to test because if they find out there’s a problem then they have to do something about it. But it is your responsibility to know. You have to humanize the problem. It’s not about devices—it’s about those child’s faces.  No dentist goes to work and says “I want to hurt someone today.” But do they go to work today and say “I want to make sure that we don’t hurt anybody, ever.” It’s a huge difference. That’s why it’s so important that the CDC reviews its guidelines.  What to do if you have an open water system Many older dental offices still use city water and can’t introduce a germicide or antimicrobial into the system. You can treat your water, but you can’t efficiently shock the water. What do they do? You should retrofit your open systems so you can shock the water. Add a closed bottle system for $200 a chair + labor. In 10 minutes you can shock them with bleach and sleep at night. You just have to take the time to do it. Recently, In Corpus Christi Texas, they had water-boil advisories. Municipal water was contaminated. If you don’t have a closed system, that effectively shuts down your practice. It’ll cost you way more than converting your dental unit to closed bottles. Plus, you have to keep tabs on your city's boiled water advisories. Keep listening to hear our conversation about tap water versus distilled water and what Kellie and Mike recommend using.  Pro Edge’s new Flow-Cytometry water testing technology Proedge has launched a Flo™ Dental Unit Waterline Testing Service Kit that allows you to get same or next-day test results. It takes one hour for them to process the results. They’re counting the bacterial cells in the water with laser technology and fluorescent dye. Why does it matter so much? Other tests can take days or even weeks to get results.  Some practices have to remain closed when their water lines are being tested—only to find out they failed. That means they have to shock their systems, restest, and wait all over again. No longer. The price of this test is only a couple percent more. It’s a premium service without the premium price. Check out the resources for a link to an amazing deal on this new product. I want people to do the testing, work with good people, and save money while doing it.  Resources & People Mentioned Special Dental Compliance ProEdge Offer Flo™ Dental Unit Waterline Testing Service Kit Dental Infection Control Washington state Mike Rust on LinkedIn Kellie Thimmes on LinkedIn ProEdge on Facebook Call ProEdge at 888-843-3343 Environmental Protection Agency (EPA) U.S. Food and Drug Administration Boil-Water Advisory Dental Unit Waterline Contamination in Anaheim Connect With Duane https://www.dentalcompliance.com/ toothcop(at)dentalcompliance.com On Facebook On Twitter On LinkedIn On Youtube

Symbiosis is the interaction between two species that offers benefits to one or both of the organisms involved. One important type of symbiosis that has been instrumental in advancing evolution is endosymbiosis, where one of the organisms lives inside the other. Endosymbiosis has typically been studied using microscopy, but Dr Toshiyuki Takahashi from the National Institute of Technology in Miyazaki, Japan, proposes that a technique called flow cytometry can offer more detailed insights into endosymbiotic relationships and advance our understanding of these important associations.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.07.23.217869v1?rss=1 Authors: Stoof, R., Grozinger, L., Tas, H., Goni-Moreno, A. Abstract: Measuring fluorescence by flow cytometry is fundamental for characterising single-cell performance. While it is known that fluorescence and scattering values tend to positively correlate, the impact of cell volume on fluorescence is typically overlooked. This makes of fluorescence values alone an inaccurate measurement for high-precision characterisations. We developed FlowScatt, an open-source software package that removes volume-dependency in the fluorescence channel. Using FlowScatt, flourescence values are re-calculated based on the unified volume per cell that arises from scattering decomposition. FlowScatt is openly available as a Python package on https://github.com/rstoof/FlowScatt. Experimental data for validation is available online. Copy rights belong to original authors. Visit the link for more info

Dr. Andrea Yu sits down with Dr. Robert Tighe to discuss everything you wanted to know about flow cytometry (but were afraid to ask).

Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations. Thanks to improvements in throughput, automation and multichannel detection capabilities, recent years have seen its use expand across a wide range of drug discovery applications. In this article, we look at novel developments in flow cytometer reagent and instrument design, and what these mean for drug discovery. By Helen Stewart-Miller and Dr Richard Massey If you'd like to view the original article then follow the link below: https://www.ddw-online.com/drug-discovery/p322918-flow-cytometry-the-advanced-systems-overcoming-drug-discovery-pain-points.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/136064/(4)-flow-cytometry.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

BD Principal Scientist, Dr. Alan Stall shares his involvement in the early days of flow cytometry, how critical standardization is for the field today, and what flow cytometry enables for tomorrow.

Stefania Arioli, UniMilano, Italy, speaks on "Flow cytometry applications in Food Microbiology: not only cell counting!". This movie is part of "Flow cytometry: from basic principles to advanced application" Course, 8-10 May 2019, ICGEB Trieste, Italy.

Enrico Lugli, Humanitas Milano, Italy, speaks on "High content flow cytometry to dissect memory T cells responses". This movie is part of "Flow cytometry: from basic principles to advanced application" Course, 8-10 May 2019, ICGEB Trieste, Italy.

Antonella Zucchetto, CRO Aviano, Italy speaks on "Flow cytometry for basic research and diagnosis of lymphoid malignancies". This movie is part of "Flow cytometry: from basic principles to advanced application" Course, 8-10 May 2019, ICGEB Trieste, Italy.

In episode ten of the 2019 R&D season, Just Science interviews Dr. Christopher Ehrhardt, professor at Virginia Commonwealth University, about a method for determining tissue type, age of evidence, and contributors from biological mixtures using cellular autofluorescence signatures. It goes without saying that cells collected from different parts of the body look different. Buccal, vaginal, epidermal, and blood cells all have unique intrinsic properties. However, when they are combined, it can be difficult to discern what components are actually in the mixture. Using Imaging Flow Cytometry, Dr. Ehrhardt has found a way to differentiate between cell types, estimate cellular age, and identify contributors in the sample. Listen in as he discusses how autofluorescence data and cellular properties are being used to analyze samples without destroying the evidence in this episode of Just Science. This season is funded by the National Institute of Justice’s Forensic Technology Center of Excellence.

Find out more about current challenges and recent developments in seen in the field of flow cytometry in this interview with Clara Brando and Ted Baginski (Eurofins; MO, USA).

Find out more about the role of exosomes in flow cytometry studies in this interview Joyce Slusser (KCAS; KS, USA).

Mark Edinger is the Scientific Advisor for Flow Cytometry at Q2 Solutions. In this episode, he describes recent advances in flow cytometry and what that means for immuno-oncology trials. New instruments, reagents and software are enabling researchers to monitor 30-some markers simultaneously to get a better picture of the tumor micro-environment and the interactions taking place. For example, there's a whole list of new checkpoint inhibitors, like PD-1, CTLA-4, CD-1-52 and a multitude of other CD-47 that have been described, and their ligands on T cells and immune cells, not just T cells, that allows the tumor to actively turn off the host response to the tumor that prevent the tumor from being killed by the immune system. We weren't aware of these, many of these, until we had the tools that allow us to look at many more markers simultaneously. For instance markers of T cell activation have been around for a long time, but that list has expanded remarkably now, and the lists of markers of T cell exhaustion have really expanded as well, and some of those were not discovered until relatively recently, in the last 5 or 6 years. Mark explained how flow cytometry is being used to determine whether a therapeutic is efficacious or not and the benefits that flow to the patient. He stressed, as others in this series have, the importance of early engagement between sponsors and their clinical trials partners. Regular phone calls and direct conversations between scientists help refine the assays to produce the desired result in terms of the information collected from a panel.  

Find out more about the flow cytometry in this Bioanalysis Zone interview with Christoph Eberle (Charles River Laboratories), as part of our 'In the Zone' feature. You can find out more about flow cytometry on the website, at: http://bit.ly/2RuwAKi

Flow cytometry is a powerful tool for cell quantitation and analysis across a wide range of clinical and research applications. Most commonly used in the fields of immunology and haematology, recent improvements in instrument automation and throughput mean that the technique is now emerging as an increasingly attractive high-throughput screening (HTS) platform in drug discovery too. Flow cytometry is a widely-used analytical method that uses light to count and characterise heterogeneous cell populations. Highly valued for its ability to measure multiple parameters simultaneously, the technique enables vast amounts of data on large, phenotypically diverse cell populations to be rapidly collected. Coupled with the fact that it is a non-destructive method that can be performed on live cells allowing further processing and analysis, it has become well-established as an important tool for both investigatory and routine analysis across a wide range of applications. This article was written by Paul Avery & Richard Massey If you'd like to view the original article then follow the link below: https://www.ddw-online.com/screening/p321757-automating-flow-cytometry-for-cell-based-screening-in-drug-discovery.html You can also download the original article pdf here: https://www.ddw-online.com/media/32/129249/(4)-automating-flow-cytometry-for-cell-based-screening.pdf For more information on Drug Discovery World, head to: https://www.ddw-online.com

How flow cytometry can help investigations into immune-mediated diseases. Flow cytometry is a technique which uses flourescent compounds of different colours to label molecules on cells. Using this approach we can investigate the cell populations responsible for causing immune-mediated diseases such as Ankylosing Spondylitis and explore how new therapies can alter the behaviour of the different cell types.

How flow cytometry can help investigations into immune-mediated diseases. Flow cytometry is a technique which uses flourescent compounds of different colours to label molecules on cells. Using this approach we can investigate the cell populations responsible for causing immune-mediated diseases such as Ankylosing Spondylitis and explore how new therapies can alter the behaviour of the different cell types.

Join us for our fourth episode of the new Myeloma Crowd Research Initiative of the proposals under consideration for the MCRI patient-led funding initiative. Dr. Bruno Paiva, PhD,  is a multiple myeloma researcher from the University of Navarra Spain specializing in minimal residual disease (MRD) detection using flow cytometry. What does the newer MRD testing mean for high-risk patients? Dr. Paiva will describe his new study to find more clues and therefore better treatments for high-risk patients. 

Background: The CD40-CD40L (CD154) costimulatory pathway plays a critical role in the pathogenesis of kidney allograft rejection. In renal transplant biopsies, CD4+ CD40L+ graft-infiltrating cells were detected during chronic rejection in contrast to acute rejection episodes. Using a rapid noninvasive FACS procedure, we were able to demonstrate CD40L upregulation in peripheral blood of patients with chronic renal allograft dysfunction. Materials and Methods: Whole blood from recipients of renal allografts was stimulated with PMA and ion-omycin and measured by flow cytometry. Patients were assigned to three groups based on transplant function. Group 1: 26 patients with excellent renal transplant function; group 2: 28 patients with impaired transplant function; group 3: 14 patients with chronic allograft dysfunction and group 4: 8 healthy controls. Results: The median percentage +/-SEM of CD4+/ CD40L+ cells stimulated ex vivo at 10 ng/ml PMA was as follows: group 1: 28.3 +/- 4.1%; group 2: 18.4 +/- 2.4%; group 3: 50.1 +/- 5.0% and group 4: 40.4 +/- 3.4%. Subdivisions of groups 2 and 3 resulted in different CD40L expression patterns. Patients with increased serum creatinine since the initial phase after transplantation ( groups 2a and 3a) revealed a higher percentage of CD4+ CD40L+ cells than patients showing a gradual increase over time ( groups 2b and 3b). Consequently, patients of group 3a exhibited a significantly reduced transplant function compared with those of group 3b. Conclusion: After PMA + ionomycin stimulation, patients with excellent kidney graft function displayed significantly reduced expression of CD40L surface molecules on CD4+ cells early after transplantation. Those with a chronic dysfunction of the renal graft showed significantly more CD4+ cells expressing CD40L compared to the other transplanted groups. These results demonstrate that the percentage of CD4+ CD40L+ cells stimulated ex vivo in peripheral blood may be a valuable marker for chronic allograft nephropathy. Copyright (C) 2004 S. Karger AG, Basel.

To investigate mechanisms of cell-mediated injury in renal inflammatory disease it is critical to determine the surface phenotype of infiltrating renal leukocyte subsets. However, the cell-specific expression of many leukocyte receptors is difficult to characterize in vivo. Here, we report a protocol based on flow cytometry that allows simultaneous characterization of surface receptor expression on different subsets of infiltrating renal leukocytes. The described technique combines an adapted method to prepare single cell suspensions from whole kidneys with subsequent four-color flow cytometry. We recently applied this technique to determine the differential expression of murine chemokine receptors CCR2 and CCR5 on infiltrating renal leukocyte subsets. In this article, we summarize our current findings on the validity of the method as compared with immunohistology and in situ hybridization in two murine models of nonimmune ( obstructive nephropathy) and immune-mediated ( lupus nephritis) inflammatory renal disease. Flow cytometry analysis revealed an accumulation of CCR5-, but not CCR2-positive lymphocytes in inflamed kidneys, compared to the peripheral blood. Particularly renal CD8(+) cells expressed CCR5 (79% in obstructed kidneys, 90% in lupus nephritis). In both models, infiltrating renal macrophages were positive for CCR2 and CCR5. These data corresponded to immunohistological and in situ hybridization results. They demonstrate that flow cytometric analysis of single cell suspensions prepared from inflamed kidneys is a rapid and reliable technique to characterize and quantify surface receptor expression on infiltrating renal leukocyte subsets.

Sun, 1 Jan 1989 12:00:00 +0100 https://epub.ub.uni-muenchen.de/9335/1/9335.pdf Cremer, Thomas; Aten, J. A.; Hetzel, J.; Diaz, Eduardo; Hausmann, Michael; Cremer, Christoph